Home > Healthcare > Analytical Instruments > Elemental Analysis > High Throughput Screening Market
High Throughput Screening Market Size
- Report ID: GMI5836
- Published Date: May 2023
- Report Format: PDF
High Throughput Screening Market Size
High Throughput Screening Market size was valued at around USD 22.1 billion in 2022 and it is estimated to reach over USD 49.8 billion in 2032. Growing focus towards implementation of ultra high throughput screening (uHTS) techniques that is capable of conducting hundreds of thousands of screening tests per day is augmenting the industry growth.
Increased funding and R&D budgets of multinational companies are driving global clinical trials, leading to market growth. HTS is finding expanded applications in stem cell research, toxicology, and other life science fields, contributing to its adoption. Open innovation models and ongoing technological advancements in HTS are further fueling market growth. Therefore, these factors are expected to support the market progression.
High-throughput screening (HTS) is a method specifically used for drug discovery that involves automated screening of huge numbers of biological and chemical compounds for a specific biological target. HTS is a preferred method for identification of biologically relevant compounds in drug discovery processes by running millions of chemical and biological tests in a short time span.
| Report Attribute | Details |
|---|---|
| Base Year: | 2022 |
| High Throughput Screening Market Size in 2022: | USD 22.1 Billion |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR: | 8.4% |
| 2032 Value Projection: | USD 49.8 Billion |
| Historical Data for: | 2018 to 2022 |
| No. of Pages: | 230 |
| Tables, Charts & Figures: | 580 |
| Segments covered: | Products and Services, Technology, Application, End-use and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
HTS is increasingly being adopted in research facilities across various domains. The method involves multiple steps, including target identification, assay development, and compound screening, each with varying time, cost, and complexity. Among these steps, assay development for primary and secondary assays is particularly expensive, requiring specialized systems. This cost barrier poses challenges for small-scale labs and academic research facilities with limited budgets.
Additionally, multinational pharma companies face increased capital investment and total cost of ownership due to the need for multiple systems. Furthermore, the scarcity of skilled personnel and the significant maintenance costs associated with these instruments are expected to impede market progress.
Frequently Asked Questions (FAQ) :
High Throughput Screening Market Scope
